From disease basics to insightful analysis of market dynamics, Glioma | Disease Landscape & Forecast | United States, EU5 provides comprehensive disease coverage addressing critical aspects of the glioma pharmaceutical market based on detailed primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a top-line review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.

Questions Answered:

  • How large is the treatable glioma population, and how will diagnosis/drug-treatment rates change over time?
  • What is the current state of treatment in glioma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
  • What pipeline products are most promising, and what sales/uptake could they secure in glioma? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the glioma market, and how will the market evolve over the forecast period?

Scope: 

Markets covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: 8 country-specific interviews with thought leaders.

Epidemiology: Diagnosed incident cases of low-grade glioma (WHO grade I-II), high-grade glioma (anaplastic glioma; WHO grade III), glioblastoma (WHO grade IV; primary cases ), and transformed cases of nonglioblastoma astrocytic glioma (WHO grade I-III; secondary cases).

Population segments in market forecast: First-line glioblastoma (newly diagnosed and transformed nonglioblastoma astrocytic glioma cases), second-line glioblastoma (first recurrence), and third-line glioblastoma (second recurrence).

Phase III: 6 drugs; Phase II: 15 drugs; coverage of selected preclinical and Phase I products.

Table of contents

  • Glioma - Landscape & Forecast - Disease Landscape & Forecast
    • Executive Summary
      • Introduction
        • Key Findings
        • Glioma Market Parameters and Forecast
        • Glioma SWOT Analysis
      • Note About Our Epidemiology Estimates
      • Forecast
        • Forecast Sales of Key Therapies in Glioblastoma
      • Etiology and Pathophysiology
        • Etiology
          • Genetic Risk Factors for Developing Glioma
          • Prognostic Factors for Developing Glioma
        • Disease Pathophysiology
          • WHO Grading System for Glioma
          • Astrocytes
          • Oligodendrocytes
          • Ependymal Cells
        • Key Pathways and Drug Targets
          • Signaling Pathways and Drug Targets Implicated in the Development of Glioma
      • Epidemiology Overview
        • Introduction
          • Key Findings
          • Incidence of Astrocytic Glioma
          • Incidence of Astrocytic Glioma per 100,000 per Year Among People Aged 20+ in 2015 and 2025
          • Relative Sizes of the Contributing Factors to the Trend in Incident Cases Over the Next Ten Years
          • Relative Sizes of the Contributing Factors to the Trend in Incident Cases of Astrocytic Glioma Over the Next Ten Years
          • Analysis of Diagnosed Incident Cases of Astrocytic Glioma by Histology in 2015
          • Diagnosed Incident Cases of Astrocytic Glioma by Histology in 2015
        • Epidemiology Populations
          • Disease Definition
          • Methods
          • Sources Used for Diagnosed Incidence of Glioma
          • Diagnosed Incident Cases of Glioma
          • Disease Definition
          • Methods
          • Sources Used for Histology in Glioma
          • Diagnosed Incident Cases of Astrocytic Glioma by Histology
          • Diagnosed Incident Cases of Oligodendroglioma by Histology
          • Diagnosed Incident Cases of Ependymal Tumors by Histology
          • Disease Definition
          • Methods
          • Sources Used for Transformation Risk
          • Transformed Cases of Astrocytic Glioma
          • Glioblastoma Patient Flow
          • Drug-Treatable Cases of Glioblastoma
          • Sources Used for Drug-Treatable Populations of Glioblastoma
          • Drug-Treated Cases of Glioblastoma
      • Current Treatment Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Treatment Overview
        • Diagnosis
          • Treatment Providers and Referral Patterns
          • Expert Insight on Diagnosis of Glioma
        • Treatment Goals
          • Key End Points Used in Clinical Trials in Glioma
          • Key Physician Insights on Clinical End Points
          • Expert Insight on Clinical End Points
          • Criteria Used to Assess Efficacy in Clinical Trials in Glioma
        • Key Current Therapies
          • Overview
          • Mechanism of Action of Key Current Drugs or Drug Classes Used for Glioma
          • Current Treatments Used for Glioma
          • Market Events Impacting the Use of Key Current Therapies in Glioma
          • Clinical Trial Outcomes for Avastin
          • Clinical Analysis of Avastin for the Treatment of Glioma
          • Advantages and Disadvantages of Avastin
          • Avastin Ongoing Clinical Development
          • Ongoing Clinical Development of Avastin
          • Expert Insight on Avastin
          • Clinical Trial Outcomes for Temozolomide
          • Clinical Analysis of Temozolomide for the Treatment of Glioma
          • Advantages and Disadvantages of Temozolomide
          • Expert Insight on Temozolomide
          • Clinical Trial Outcomes for the PCV Regimen
          • Clinical Analysis of PCV in the Treatment of Glioma
          • Advantages and Disadvantages of the PCV Regimen
          • Expert Insight on PCV Regimen
          • Clinical Analysis of Gliadel Wafer for the Treatment of Glioma
          • Expert Insight on Gliadel Wafer
          • Clinical Trial Outcomes of Optune
          • Clinical Analysis of Optune in the Treatment of Glioma
          • Advantages and Disadvantages of Optune
          • Expert Insight on Optune
        • Medical Practice
          • Drug-Treatable Population: Low-Grade Glioma
          • Drug-Treatable Population: Anaplastic Glioma
          • Drug-Treatable Population: Newly Diagnosed Glioblastoma
          • Drug-Treatable Population: Recurrent Glioblastoma
          • United States
          • Europe
          • Treatment Decision Tree for Low-Grade Glioma
          • Treatment Decision Tree for High-Grade Glioma
          • Treatment Decision Tree for Glioblastoma
          • Glioma Treatment Guidelines, by Market
      • Unmet Need Overview
        • Introduction
          • Key Findings
          • Expert Insight
        • Attainment of Unmet Needs
          • Current Attainment of Unmet Needs in Glioma
          • Future Attainment of Unmet Needs in Glioma
          • Top Unmet Needs in Glioma-Current and Future Attainment
          • Expert Insight on Unmet Need in Glioma
      • Emerging Therapies Overview
        • Introduction
          • Key Findings
          • Expert Insight
          • Pipeline Overview
          • PipelineTrends for Glioma
        • Late-Phase Pipeline Analysis
          • Notable Developments in the Late-Phase Pipeline for Glioma
          • Therapies in Late-Phase Development for Glioma
          • Estimated Approval Dates of Key Emerging Therapies for the Treatment of Glioma
          • Emerging Therapies with Sales Potential in Glioma: Population Positioning
        • Orphan-Drug Designation
          • Expanded Market Exclusivity
          • Tax Credits
          • Support During the Drug Approval Process
          • Grants
          • Market Exclusivity
          • Fee Reductions
        • Patient Registries
          • Patient Registries for Glioma
          • Prominent Glioma Patient Organizations
        • Key Emerging Therapies
          • Key Results from Select Clinical Trials Investigating DCVax-L in Glioblastoma
          • DCVax-L Clinical Development
          • Key Ongoing Clinical Trials for DCVax-L for the Treatment of Glioblastoma
          • Expert Insight
          • Expert Insight on DCVax-L
          • Expectations for Launch and Sales Opportunity of DCVax-L in Glioblastoma
          • Key Results from Select Clinical Trials Investigating ICT-107 in Glioblastoma
          • ICT-107 Clinical Development
          • Key Ongoing Clinical Trials for ICT-107 for the Treatment of Glioblastoma
          • Expert Insight
          • Expert Insight on ICT-107
          • Expectations for Launch of ICT-107 in Glioblastoma
          • Key Results from Select Clinical Trials Investigating Vocimagene Amiretrorepvec in Glioblastoma
          • Vocimagene Amiretrorepvec Clinical Development
          • Key Ongoing Clinical Trials of Vocimagene Amiretrorepvec for High-Grade Gliomas
          • Expert Insight
          • Expert Insight on Vocimagene Amiretrorepvec
          • Expectations for Launch and Sales Opportunity of Vocimagene Amiretrorepvec in Glioblastoma
          • Key Results from Select Clinical Trials Investigating Ofranergene Obadenovec in Glioblastoma
          • Ofranergene Obadenovec Clinical Development
          • Key Ongoing Clinical Trials for Ofranogene Obadenovec for the Treatment of Glioblastoma
          • Expert Insight
          • Expert Insight
          • Expectations for Launch and Sales Opportunity of Ofranergene Obadenovec in Glioblastoma
          • Key Results from Select Clinical Trials Investigating Opdivo in Glioblastoma
          • Opdivo Clinical Development
          • Key Ongoing Clinical Trials for Opdivo for the Treatment of Glioblastoma
          • Expert Insight
          • Expert Insight on Opdivo
          • Expectations for Approval and Sales Opportunity of Opdivo in Glioblastoma
          • Key Results from Select Clinical Trials Investigating Depatuxizumab Mafodotin in Glioma
          • Depatuxizumab Mafodotin Clinical Development
          • Key Ongoing Clinical Trials for Depatuxizumab Mafodotin for the Treatment of Glioblastoma
          • Expert Insight
          • Expert Insight on Depatuxizumab Mafodotin
          • Expectations for Launch and Sales Opportunity of Depatuxizumab Mafodotin in Glioblastoma
        • Early-Phase Pipeline Analysis
          • Select Early-Phase Small-Molecule Inhibitors in Development for Glioma
          • Select Early-Phase Fusion Proteins in Development for Glioma
          • Select Early-Phase DNA-Modifying Agents in Development for Glioma
          • Select Early-Phase Viral and Cell-Based Therapies in Development for Glioma
          • Select Early-Phase Therapeutic Vaccines in Development for Glioma
          • Select Early-Phase Immune Checkpoint Inhibitors in Development for Glioma
      • Access and Reimbursement Overview
        • Region-Specific Reimbursement Practices
          • Reimbursement Environment for Glioblastoma Therapies in the United States
          • Reimbursement Environment for Glioblastoma Therapies in the EU5
        • U.S. Reimbursement Dynamics
          • Current Coverage Status of Key Therapies for Glioblastoma
          • Future Coverage Status of Current Therapies for Glioblastoma
        • U.S. Access & Reimbursement Considerations for Emerging Therapies
          • Access & Reimbursement Considerations for Emerging Glioblastoma Therapies in the United States
          • Potential Placement of DCVax-L in Glioblastoma at Various Price Points
      • Methodology
        • Appendix
          • Key Abbreviations Related to Glioma
          • Brands, Marketers, and Generic Availability of Key Therapies for Glioma, by Market
          • Experts Interviewed
          • Bibliography

      Author(s): Aarushi Kashyap, M.Tech.

      Aarushi Kashyap is a Senior Insights Analyst in Oncology team at Decision Resources Group, based out of Gurgaon office in India.

      She comes with a work experience of 4 years as Business Analyst with practice across multiple oncology indications in various functions in Competitive Intelligence and Secondary Research, including pipeline analysis, competitive product reporting, clinical trials assessment and benchmarking, clinical and competitor landscaping, therapy area deep dive reporting, ad-hoc news tracking etc. She has attended various big and small oncology medical congresses across US and Europe in parallel to creating pre- and post-conference data summaries with implications and schedule trackers for abstracts of interest delivering to directly to clients. She has earned her Master's and Bachelor's in Technology in Biotechnology from Jaypee Institute of Information Technology University.


      Related Reports

      Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

      In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

      View Details